Serina Therapeutics (SER) reported that the NYSE has accepted the company’s business plan to regain compliance with the continued listing standards set forth in Section 1003 of the NYSE American Company Guide.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SER:
- Serina Therapeutics Announces Premium Private Placement Financing
- Nasus Pharma’s NS002 Demonstrates Consistent Early Advantage in Epinephrine Delivery (NYSE: NSRX)
- Serina Therapeutics names Greg Bailey co-chairman
- Serina Therapeutics Advances SER-252 Parkinson’s Trial, Marking a Key Early Milestone for Investors
- Serina Therapeutics doses first patient in SER-252 trial